Liver Cirrhosis D008103

Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Liver Cirrhosis

Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Fibrosis » Liver Cirrhosis

Description

Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.   MeSH

Subtype Terms (3)

Liver Cirrhosis, Alcoholic
14 drugs (9 approved, 5 experimental)

Liver Cirrhosis, Biliary
52 drugs (24 approved, 28 experimental)


Phase 4 Indicated Drugs (84)

Phase 3 Indicated Drugs (80)

Key: D008103 (79) Subtype (1)

Phase 2 Indicated Drugs (81)


Organization Involved with Phase 4 Indications (61)

Key: D008103 (59) Subtype (2)

Organization Involved with Phase 3 Indications (73)

Key: D008103 (72) Subtype (1)

Organization Involved with Phase 2 Indications (93)

Key: D008103 (87) Subtype (6)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.